Valuation : Insulet Corporation

Market Cap 10.44B 8.99B 8.43B 7.71B 14.4B 987B 14.51B 99.75B 38.85B 505B 39.22B 38.36B 1,625B P/E 2026 *
24.5x
P/E 2027 * 19.7x
Enterprise Value 10.49B 9.03B 8.47B 7.75B 14.47B 992B 14.58B 100B 39.03B 507B 39.4B 38.54B 1,633B EV / Sales 2026 *
3.19x
EV / Sales 2027 * 2.7x
Free-Float
97.63%
Yield 2026 *
-
Yield 2027 * -
1 day+1.65%
1 week+5.00%
Current month+1.29%
1 month-11.27%
3 months+5.08%
6 months-37.74%
Current year-47.02%
1 week 142
Extreme 142.005
151.5
1 month 126.4
Extreme 126.4
155.17
Current year 126.4
Extreme 126.4
299.8
1 year 126.4
Extreme 126.4
354.88
3 years 125.82
Extreme 125.82
354.88
5 years 125.82
Extreme 125.82
354.88
10 years 30.69
Extreme 30.69
354.88
Manager TitleAgeSince
Chief Executive Officer 55 27/04/2025
Director of Finance/CFO 53 29/09/2025
Compliance Officer 50 30/11/2022
Director TitleAgeSince
Chairman 61 31/12/2018
Director/Board Member 61 26/07/2015
Director/Board Member 59 09/08/2017
Date Insider Type Main position Quantity % Market Cap. Importance
21/08/26 Buy

Chief Executive Officer

1,100 0.0016%
01/08/26 Tax

Head of Human Resources

-244 0.0003%
01/07/26 Free

Director

1,355 0.0019%
Change 5-day change 1-year change 3-year change Capi.($)
+1.65%+5.00%-56.17%-21.65% 10.44B
-1.52%-2.51%-17.70%+5.78% 188B
+1.00%+3.48%+0.92%+13.36% 119B
+0.26%+4.98%+14.26%+92.74% 64.35B
-1.31%-1.09%+22.44%+46.84% 52.59B
+0.05%-0.27%-1.05%-32.62% 51.11B
+0.02%+0.47%+13.67%-11.96% 33.85B
+0.80%+5.60% - - 32.1B
+0.03%-0.97%+37.67%-15.93% 24.12B
-1.44%-4.21%-7.37%+11.97% 23.39B
Average -0.05%+0.41%+0.74%+9.84% 59.94B
Weighted average by Cap. -0.34%-0.51%-1.00%+15.35%

Financials

2026 *2027 *
Net sales 3.29B 2.83B 2.65B 2.43B 4.53B 311B 4.57B 31.4B 12.23B 159B 12.35B 12.08B 511B 3.74B 3.22B 3.02B 2.77B 5.16B 354B 5.2B 35.76B 13.93B 181B 14.06B 13.75B 583B
Net income 427M 367M 344M 315M 588M 40.33B 593M 4.07B 1.59B 20.61B 1.6B 1.57B 66.37B 535M 461M 432M 395M 738M 50.6B 744M 5.11B 1.99B 25.86B 2.01B 1.97B 83.29B
Net Debt 49.62M 42.7M 40.07M 36.66M 68.42M 4.69B 68.96M 474M 185M 2.4B 186M 182M 7.72B -322M -277M -260M -238M -444M -30.47B -448M -3.08B -1.2B -15.57B -1.21B -1.18B -50.16B
Logo Insulet Corporation
Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (98.7%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (1.3%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). At the end of 2025, the group had 2 production sites located in the United States and in China. The United States account for 72.2% of net sales.
Employees
5,400
Date Price Change Volume
03/09/26 US$150.58 +1.65% 1,157,659
02/09/26 US$148.14 -0.16% 1,113,956
01/09/26 US$148.38 -0.19% 1,288,263
31/08/26 US$148.66 +2.43% 6,635,039
28/08/26 US$145.13 +1.20% 1,043,384
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
150.58USD
Average target price
171.91USD
Spread / Average Target
+14.16%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PODD Stock